Search

everythinglearnresearchcommunity

for

Search:↓

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

The document concludes that there have been significant improvements in diagnosing and treating skin diseases, including melanoma, with new techniques and therapies.

A hospital outbreak of catheter infections in calves was caused by a bacteria from a beef herd, leading to longer hospital stays, more drug use, and calf deaths.

Taking spironolactone doesn't increase the chance of breast cancer coming back.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Core symptoms in breast cancer chemotherapy remain stable, aiding targeted interventions.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Chemotherapy caused a woman's permanent hair loss and early menopause.

Chemotherapy can cause hair changes similar to alopecia areata, which might lead to misdiagnosis.

Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.

Chemotherapy can cause significant hair thinning and changes in hair texture, while tamoxifen has a smaller effect.

Scalp cooling to prevent hair loss from chemotherapy works for some but not all, and studying hair damage markers could improve prevention and treatment.

Scalp cooling therapy helps preserve hair during chemotherapy for most patients.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

The study found unique skin changes in a rare type of alopecia linked to a skin condition called linear morphea.

The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

Some drugs can cause permanent hair loss, though it's rare.

HER2-targeted or hormonal therapies improve quality of life for Sudanese breast cancer patients.

Vitamin C was found to effectively treat prickly heat in children.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Female pattern hair loss is common, linked to polycystic ovarian syndrome, and treated with topical Minoxidil.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Breast cancer skin metastases are rare, look different, and can be confused with other skin issues, so a biopsy is needed for accurate diagnosis.

The review shows how to properly diagnose and treat the loss of eyebrow and eyelash hair.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.